메뉴 건너뛰기




Volumn 14, Issue 2, 2015, Pages 407-418

A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PHOSPHOTRANSFERASE; SKLB 261; STAT3 PROTEIN; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; 2 AMINOPURINE; ANGIOGENESIS INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN; SKLB261;

EID: 84923342784     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0485     Document Type: Article
Times cited : (27)

References (46)
  • 3
    • 77951755278 scopus 로고    scopus 로고
    • Pancreatic cancer
    • Hidalgo M. Pancreatic cancer. New Engl J Med 2010;362:1605-17.
    • (2010) New Engl J Med , vol.362 , pp. 1605-1617
    • Hidalgo, M.1
  • 4
    • 8244254377 scopus 로고    scopus 로고
    • Improvements in survival and clinical benefi twith gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
    • Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefi twith gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
    • (1997) J Clin Oncol , vol.15 , pp. 2403-2413
    • Burris, H.A.1    Moore, M.J.2    Andersen, J.3    Green, M.R.4    Rothenberg, M.L.5    Modiano, M.R.6
  • 5
    • 33846405332 scopus 로고    scopus 로고
    • Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial
    • Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-77.
    • (2007) JAMA , vol.297 , pp. 267-277
    • Oettle, H.1    Post, S.2    Neuhaus, P.3    Gellert, K.4    Langrehr, J.5    Ridwelski, K.6
  • 6
    • 27544500200 scopus 로고    scopus 로고
    • A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma
    • Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618-28.
    • (2005) Surgery , vol.138 , pp. 618-628
    • Farnell, M.B.1    Pearson, R.K.2    Sarr, M.G.3    DiMagno, E.P.4    Burgart, L.J.5    Dahl, T.R.6
  • 7
    • 0031918491 scopus 로고    scopus 로고
    • DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma
    • Allison DC, Piantadosi S, Hruban RH, Dooley WC, Fishman EK, Yeo CJ, et al. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 1998;67:151-9.
    • (1998) J Surg Oncol , vol.67 , pp. 151-159
    • Allison, D.C.1    Piantadosi, S.2    Hruban, R.H.3    Dooley, W.C.4    Fishman, E.K.5    Yeo, C.J.6
  • 8
    • 52149123619 scopus 로고    scopus 로고
    • Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
    • Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
    • (2008) Science , vol.321 , pp. 1801-1806
    • Jones, S.1    Zhang, X.2    Parsons, D.W.3    Lin, J.C.4    Leary, R.J.5    Angenendt, P.6
  • 10
    • 34248141223 scopus 로고    scopus 로고
    • Tumor-stroma interactions in pancreatic ductal adenocarcinoma
    • Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007;6:1186-97.
    • (2007) Mol Cancer Ther , vol.6 , pp. 1186-1197
    • Mahadevan, D.1    Von Hoff, D.D.2
  • 11
    • 0026462778 scopus 로고
    • Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha
    • Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992;90:1352-60.
    • (1992) J Clin Invest , vol.90 , pp. 1352-1360
    • Korc, M.1    Chandrasekar, B.2    Yamanaka, Y.3    Friess, H.4    Buchier, M.5    Beger, H.G.6
  • 15
    • 6044241807 scopus 로고    scopus 로고
    • The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: Poor prognosis in patients with pancreatic ductal adenocarcinoma
    • Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004;29:e1-8.
    • (2004) Pancreas , vol.29 , pp. e1-e8
    • Ueda, S.1    Ogata, S.2    Tsuda, H.3    Kawarabayashi, N.4    Kimura, M.5    Sugiura, Y.6
  • 16
    • 0032423809 scopus 로고    scopus 로고
    • Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer
    • Dong M, Nio Y, Guo KJ, Tamura K, Tian YL, Dong YT. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 1998;18:4613-9.
    • (1998) Anticancer Res , vol.18 , pp. 4613-4619
    • Dong, M.1    Nio, Y.2    Guo, K.J.3    Tamura, K.4    Tian, Y.L.5    Dong, Y.T.6
  • 17
    • 0033805783 scopus 로고    scopus 로고
    • Molecular prognostic markers in pancreatic cancer
    • Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control 2000;7:421-7.
    • (2000) Cancer Control , vol.7 , pp. 421-427
    • Coppola, D.1
  • 18
    • 33644647192 scopus 로고    scopus 로고
    • Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model
    • Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006;168:962-72.
    • (2006) Am J Pathol , vol.168 , pp. 962-972
    • Trevino, J.G.1    Summy, J.M.2    Lesslie, D.P.3    Parikh, N.U.4    Hong, D.S.5    Lee, F.Y.6
  • 20
    • 1642551021 scopus 로고    scopus 로고
    • Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells
    • Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 2004;10:2307-18.
    • (2004) Clin Cancer Res , vol.10 , pp. 2307-2318
    • Duxbury, M.S.1    Ito, H.2    Zinner, M.J.3    Ashley, S.W.4    Whang, E.E.5
  • 21
    • 2942607458 scopus 로고    scopus 로고
    • siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity
    • Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg 2004;198:953-9.
    • (2004) J Am Coll Surg , vol.198 , pp. 953-959
    • Duxbury, M.S.1    Ito, H.2    Zinner, M.J.3    Ashley, S.W.4    Whang, E.E.5
  • 22
    • 9744242077 scopus 로고    scopus 로고
    • Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice
    • Yezhelyev MV, Koehl G, Guba M, Brabletz T, Jauch KW, Ryan A, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 2004;10:8028-36.
    • (2004) Clin Cancer Res , vol.10 , pp. 8028-8036
    • Yezhelyev, M.V.1    Koehl, G.2    Guba, M.3    Brabletz, T.4    Jauch, K.W.5    Ryan, A.6
  • 23
    • 77953898050 scopus 로고    scopus 로고
    • Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma
    • Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D, et al. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2010;139:292-303.
    • (2010) Gastroenterology , vol.139 , pp. 292-303
    • Morton, J.P.1    Karim, S.A.2    Graham, K.3    Timpson, P.4    Jamieson, N.5    Athineos, D.6
  • 24
    • 0034614637 scopus 로고    scopus 로고
    • The hallmarks of cancer
    • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
    • (2000) Cell , vol.100 , pp. 57-70
    • Hanahan, D.1    Weinberg, R.A.2
  • 25
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: The next generation
    • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
    • (2011) Cell , vol.144 , pp. 646-674
    • Hanahan, D.1    Weinberg, R.A.2
  • 26
    • 0028929803 scopus 로고
    • Angiogenesis in cancer, vascular, rheumatoid and other disease
    • Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
    • (1995) Nat Med , vol.1 , pp. 27-31
    • Folkman, J.1
  • 27
    • 50249087586 scopus 로고    scopus 로고
    • A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin formetastatic pancreatic cancer: Is an anti-VEGF strategy still applicable?
    • Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, et al. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin formetastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 2008;26:463-71.
    • (2008) Invest New Drugs , vol.26 , pp. 463-471
    • Ko, A.H.1    Dito, E.2    Schillinger, B.3    Venook, A.P.4    Xu, Z.5    Bergsland, E.K.6
  • 28
    • 79958119999 scopus 로고    scopus 로고
    • Anti-angiogenic agents in pancreatic cancer: A review
    • Assifi MM, Hines OJ. Anti-angiogenic agents in pancreatic cancer: a review. Anticancer Agents Med Chem 2011;11:464-9.
    • (2011) Anticancer Agents Med Chem , vol.11 , pp. 464-469
    • Assifi, M.M.1    Hines, O.J.2
  • 29
    • 84870998201 scopus 로고    scopus 로고
    • Structural optimization and structure-activity relationships of N2- (4-(4-Methylpiperazin-1-yl) phenyl)- N8- phenyl-9H-purine-2, 8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations
    • Yang J, Wang LJ, Liu JJ, Zhong L, Zheng RL, Xu Y, et al. Structural optimization and structure-activity relationships of N2- (4-(4-Methylpiperazin-1-yl) phenyl)- N8- phenyl-9H-purine-2, 8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations. J Med Chem 2012;55:10685-99.
    • (2012) J Med Chem , vol.55 , pp. 10685-10699
    • Yang, J.1    Wang, L.J.2    Liu, J.J.3    Zhong, L.4    Zheng, R.L.5    Xu, Y.6
  • 30
    • 66149163097 scopus 로고    scopus 로고
    • Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
    • Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009;15:3484-94.
    • (2009) Clin Cancer Res , vol.15 , pp. 3484-3494
    • Naumov, G.N.1    Nilsson, M.B.2    Cascone, T.3    Briggs, A.4    Straume, O.5    Akslen, L.A.6
  • 31
    • 79960957703 scopus 로고    scopus 로고
    • Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis
    • Gao Y, Jia Z, Kong X, Li Q, Chang DZ, Wei D, et al. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res 2011;71:5182-93.
    • (2011) Cancer Res , vol.71 , pp. 5182-5193
    • Gao, Y.1    Jia, Z.2    Kong, X.3    Li, Q.4    Chang, D.Z.5    Wei, D.6
  • 32
    • 79551692141 scopus 로고    scopus 로고
    • Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth
    • Nagaraj NS, Washington MK, Merchant NB. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin Cancer Res 2011;17:483-93.
    • (2011) Clin Cancer Res , vol.17 , pp. 483-493
    • Nagaraj, N.S.1    Washington, M.K.2    Merchant, N.B.3
  • 34
    • 79960222273 scopus 로고    scopus 로고
    • A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors
    • Zhao C, Wang X, Zhao Y, Li Z, Lin S, Wei Y, et al. A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors. PLoS ONE 2011;6:e21768.
    • (2011) PLoS ONE , vol.6 , pp. e21768
    • Zhao, C.1    Wang, X.2    Zhao, Y.3    Li, Z.4    Lin, S.5    Wei, Y.6
  • 35
    • 84875993686 scopus 로고    scopus 로고
    • Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals
    • Miyabayashi K, Ijichi H, Mohri D, Tada M, Yamamoto K, Asaoka Y, et al. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res 2013;73:2221-34.
    • (2013) Cancer Res , vol.73 , pp. 2221-2234
    • Miyabayashi, K.1    Ijichi, H.2    Mohri, D.3    Tada, M.4    Yamamoto, K.5    Asaoka, Y.6
  • 37
    • 0032771840 scopus 로고    scopus 로고
    • The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma
    • Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin Cancer Res 1999;5:2205-12.
    • (1999) Clin Cancer Res , vol.5 , pp. 2205-2212
    • Miknyoczki, S.J.1    Chang, H.2    Klein-Szanto, A.3    Dionne, C.A.4    Ruggeri, B.A.5
  • 40
    • 67650924582 scopus 로고    scopus 로고
    • Pancreatic cancer: Molecular pathogenesis and new therapeutic targets
    • Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 2009;6:412-22.
    • (2009) Nat Rev Gastroenterol Hepatol , vol.6 , pp. 412-422
    • Wong, H.H.1    Lemoine, N.R.2
  • 41
    • 57349147100 scopus 로고    scopus 로고
    • Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: An involvement of epidermal growth factor receptor signaling
    • Ischenko I, Camaj P, Seeliger H, Kleespies A, Guba M, De Toni EN, et al. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling. Oncogene 2008;27:7212-22.
    • (2008) Oncogene , vol.27 , pp. 7212-7222
    • Ischenko, I.1    Camaj, P.2    Seeliger, H.3    Kleespies, A.4    Guba, M.5    De Toni, E.N.6
  • 42
    • 20944441928 scopus 로고    scopus 로고
    • Validating Stat3 in cancer therapy
    • Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005;11:595-6.
    • (2005) Nat Med , vol.11 , pp. 595-596
    • Darnell, J.E.1
  • 43
    • 72549108620 scopus 로고    scopus 로고
    • Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer
    • Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, et al. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 2009;15:6852-61.
    • (2009) Clin Cancer Res , vol.15 , pp. 6852-6861
    • Byers, L.A.1    Sen, B.2    Saigal, B.3    Diao, L.4    Wang, J.5    Nanjundan, M.6
  • 44
    • 0035799531 scopus 로고    scopus 로고
    • Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells
    • Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513.
    • (2001) Oncogene , vol.20 , pp. 2499-2513
    • Garcia, R.1    Bowman, T.L.2    Niu, G.3    Yu, H.4    Minton, S.5    Muro-Cacho, C.A.6
  • 45
    • 79953756112 scopus 로고    scopus 로고
    • Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer
    • Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011;19:456-69.
    • (2011) Cancer Cell , vol.19 , pp. 456-469
    • Lesina, M.1    Kurkowski, M.U.2    Ludes, K.3    Rose-John, S.4    Treiber, M.5    Kloppel, G.6
  • 46
    • 79953761842 scopus 로고    scopus 로고
    • Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression
    • Fukuda A, Wang SC, Morris JPt, Folias AE, Liou A, Kim GE, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011;19:441-55.
    • (2011) Cancer Cell , vol.19 , pp. 441-455
    • Fukuda, A.1    Wang, S.C.2    Morris, J.3    Folias, A.E.4    Liou, A.5    Kim, G.E.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.